Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of rozanolixizumab in adults with persistent or chronic primary immune thrombocytopenia
jRCT2080225255Phase 3Terminated
- Sponsor
- UCB
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Rozanolixizumab with Placebo (2 arms). Started Jul 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2080225255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225255.